Harding M A, Gattone V H, Grantham J J, Calvet J P
Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City.
Kidney Int. 1992 Feb;41(2):317-25. doi: 10.1038/ki.1992.44.
The C57BL/6J-cpk mouse has a form of autosomal-recessive polycystic kidney disease characterized by the rapid growth of large collecting duct cysts and the development of severe renal failure usually by three to four weeks of age. Previous studies had shown higher steady-state levels of proto-oncogene mRNA in these cystic kidneys. It is now shown using nuclear run-on transcription that the c-fos and c-myc proto-oncogenes are transcribed at higher rates in cystic kidneys, and thus that increased transcription, in part, may account for the increased mRNA levels. c-myc mRNA was detected by in situ hybridization in nephron anlagen and elongating tubules of normal and cystic kidneys during late fetal and early neonatal kidney development. Localization of c-myc expression in the normal kidney decreased with age over the three-week postnatal period. By contrast, c-myc mRNA was found in cysts as early as three days of age, with increased levels at two and three weeks. c-myc expression was also elevated in apparently normal, non-dividing proximal tubules in three-week-old cystic animals. On the basis of these findings, we suggest that c-myc expression is linked to the proliferation of cells engaged in the primary cystogenic process, and that expression of this gene in proximal tubule cells of severely azotemic animals reflects the compensatory response of residual tubular epithelial cells to progressive renal dysfunction.
C57BL/6J-cpk小鼠患有一种常染色体隐性多囊肾病,其特征是集合管大囊肿迅速生长,通常在3至4周龄时发展为严重肾衰竭。先前的研究表明,这些多囊肾中原癌基因mRNA的稳态水平较高。现在通过核转录实验表明,c-fos和c-myc原癌基因在多囊肾中的转录速率更高,因此转录增加可能部分解释了mRNA水平的升高。在胎儿后期和新生儿早期肾脏发育过程中,通过原位杂交在正常和多囊肾的肾单位原基和伸长的肾小管中检测到c-myc mRNA。在出生后的三周内,正常肾脏中c-myc表达的定位随年龄增长而降低。相比之下,早在3日龄的囊肿中就发现了c-myc mRNA,在2周和3周时水平升高。在3周龄的多囊动物中,明显正常的、不分裂的近端小管中c-myc表达也升高。基于这些发现,我们认为c-myc表达与参与原发性囊肿形成过程的细胞增殖有关,并且该基因在严重氮质血症动物近端小管细胞中的表达反映了残余肾小管上皮细胞对进行性肾功能不全的代偿反应。